DEFENCE THERAPEUTICS A - DTCFF STOCK NEWS

Defence Therapeutics Inc. announces the closing of the 1st tranche of its non-brokered private placement, raising $850,500.00. The Company intends to use the net proceeds to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX administered intratumorally in patients with stage IIIB to IV melanoma, and for general working capital. The Offering consists of units priced at $1.50 per Unit, each containing one common share and one common share purchase warrant. The Company paid a cash finder's fee of $68,040.00 and issued Finder's Warrants to a certain qualified arm's length finder. All securities issued in connection with the Offering are subject to a statutory hold period of four months plus a day from their date of issue in accordance with applicable securities legislation.

Defence Therapeutics Inc. announces an amendment to its financing, conducting a non-brokered private placement of up to $2,250,000. The company will use the net proceeds to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX administered intratumorally in patients with stage IIIB to IV melanoma, and for general working capital.

Defence Therapeutics Inc. announces a non-brokered private placement of up to $2,790,000 to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX®. The company's common shares have been upgraded to OTCQB, and are now trading under the symbol 'DTCFF'.

Defence Therapeutics Inc. (DTC) successfully tested a new formulation of its ACCUM-002TM Dimer CDCA-SV40, known as AccuTOX®, for lung-established tumors. The drug demonstrated enhanced therapeutic properties and broader application in cancer therapeutics, with successful preclinical studies and FDA clearance to begin a Phase I trial in patients with melanoma. The global cancer therapeutics market size is expected to reach US$393.61 billion by 2032, presenting significant growth opportunities for the company.

Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) announces FDA approval for Phase I clinical trial of AccuTOX™, a first-in-class injectable anticancer molecule for solid cancer tumors.

Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) has received clearance from the U.S. FDA for its Phase I clinical trial of ACCUM-002TM Dimer CDCA-SV40, also known as AccuTOX®, as an injectable anticancer molecule for the treatment of solid cancer tumors. This marks a significant milestone for Defence in the immune-oncology field, positioning AccuTOX® as the company's flagship asset in the anti-cancer therapeutics field. The approval reflects the company's commitment to addressing unmet clinical needs and becoming a global leader in innovative anti-cancer therapies.

Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) is pleased to announce the successful submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its ACCUM-002TM Dimer CDCA-SV40, AccuTOX®, an injectable anticancer molecule. The IND application includes preclinical animal testing data, pharmacology, pharmacokinetics, and toxicology studies, and details of drug substance and product manufacturing. The company aims to advance AccuTOX® into a Phase I clinical trial by Q1-Q2 2024. The primary objective of the upcoming trial is to identify the best therapeutic dosing range for co-administration with Opdulag®, a BMS product, in treating patients with solid tumors.

Defence Therapeutics Inc., a Canadian biopharmaceutical company, has received a Notice of allowance for its Canadian patent application. The patent covers key vaccine platform technologies that enhance the immunogenicity of protein subunit vaccines, potentially improving their efficacy and lowering antigen dose required. The company already has a counterpart US patent. Defence intends to leverage these patents to secure broad patent protection in other markets and explore licensing and partnering opportunities. The global oncology market is predicted to be worth around $536.01 billion by 2029.

Defence Therapeutics announces discovery of novel function for AccuTOX® in cancer vaccine engineering